– USA, FL – NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, announced the appointment of Dr. Marjorie Green (MD) to its Board of Directors, effective June 19, 2025.
About Dr. Marjorie Green
Dr. Marjorie Green is SVP and Head of Oncology, Global Clinical Development at Merck. With her seasoned executive experience with extensive experience in the life sciences industry, she brings a strong track record of leadership in oncology, corporate strategy, and business development. As Head of Oncology, Global Clinical Development at Merck, a premier biopharmaceutical company, she oversees the company’s research for its single biggest area of commercial revenue and pipeline investment.
Before joining Merck, Dr. Green served as SVP and Head of Late-Stage Development at Seagen. Before that, Dr. Green was VP of Product Development and Global Head of the Breast and Gynecologic Cancer Franchise at Genentech. She began her career as a Medical Oncologist and Associate Professor at MD Anderson Cancer Center, where she later became the Medical Director of the Nellie B. Connally Breast Center. Dr. Green earned her BA in History from the University of Notre Dame and her MD from the University of Texas Medical Branch. She completed her residency in internal medicine at the University of Virginia School of Medicine and her medical oncology fellowship at the University of Texas MD Anderson Cancer Center.
About NeoGenomics, Inc.
NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom.
For more: https://neogenomics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.